Aurinia Pharmaceuticals Stock
Aurinia Pharmaceuticals Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Kevin C. Tang
- Employees
- 128
- Market cap
- $2.2 B
- IPO
- 03/09/2014
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies. The core mission of the firm is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Aurinia Pharmaceuticals stock: price history
1D
-1.3%
1W
-0.8%
1M
-2.7%
6M
+2.9%
YTD
+3.5%
1Y
+42.9%
2Y
+129.9%
5Y
-19.7%
10Y
+299.8%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~54% stronger price swings than usual
Aurinia Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Aurinia Pharmaceuticals
Analyst assessment of Aurinia Pharmaceuticals
PRICE TARGET LOW
US$16.00
CONSENSUS
US$16.00
MEDIAN
US$16.00
PRICE TARGET HIGH
US$16.00
0
STRONG BUY
11
BUY
4
HOLD
0
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 07/08/2026
Aurinia Pharmaceuticals stock metrics
P/E
7
P/B
3.49
EV/EBITDA
11.04
RETURN ON EQUITY
6.1%
NET MARGIN
45.0%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.1%
FLOAT SHARES
129,216,633
AVG. DAILY VOLUME (30D)
837,870
Insider transactions (SEC)
Robertson Stephen P.
Robertson Stephen P.
TANG KEVIN
TANG KEVIN
TANG KEVIN
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Aurinia Pharmaceuticals stock
What does Aurinia Pharmaceuticals do?
Aurinia Pharmaceuticals Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Kevin C. Tang, the company employs around 128 people.
The IPO was on 03/09/2014; the stock trades on NASDAQ under the ticker AUPH.
What do analysts say about Aurinia Pharmaceuticals stock?
15 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$16.00, ranging from US$16.00 to US$16.00, with a median of US$16.00.
This is an external assessment, not a statement by Market Jury.
When does Aurinia Pharmaceuticals report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 54% stronger than usual.
Does Aurinia Pharmaceuticals pay a dividend?
No, Aurinia Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Aurinia Pharmaceuticals?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Aurinia Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Aurinia Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.